Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:alsoKnownAs |
gptkb:CMX001
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:smallpox |
| gptkbp:ATCCode |
J05AB16
|
| gptkbp:brand |
gptkb:Tembexa
|
| gptkbp:CASNumber |
444805-28-1
|
| gptkbp:derivedFrom |
gptkb:cidofovir
|
| gptkbp:developedBy |
gptkb:Chimerix
|
| gptkbp:hasMolecularFormula |
C27H52N3O7P
|
| https://www.w3.org/2000/01/rdf-schema#label |
brincidofovir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
DNA polymerase inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
elevated liver enzymes
gastrointestinal symptoms |
| gptkbp:usedFor |
treatment of orthopoxvirus infections
|
| gptkbp:bfsParent |
gptkb:Vaccinia_virus
|
| gptkbp:bfsLayer |
6
|